Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
Fiche publication
Date publication
décembre 2014
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme
Tous les auteurs :
Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J,
Lien Pubmed
Résumé
The prognostic value of KRAS mutations in colon adenocarcinoma is controversial. We examined this question as an ancillary study of the PETACC8 phase III trial.
Mots clés
Aged, Antibodies, Monoclonal, Humanized, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Cetuximab, Colonic Neoplasms, drug therapy, Exons, Female, Fluorouracil, Genes, ras, Humans, Leucovorin, Male, Middle Aged, Mutation, Organoplatinum Compounds, Prognosis, Proto-Oncogene Proteins B-raf, genetics
Référence
Ann. Oncol.. 2014 Dec;25(12):2378-85